Prognostic models for advanced melanoma patients treated with anti-PD-1 monotherapy.

被引：0
|
作者：
Bai, Xue
Kim, Michelle S.
Kasumova, Gyulnara G.
Cohen, Justine Vanessa
Lawrence, Donald P.
Freedman, Christine
Fadden, Riley
Rubin, Krista M.
Sharova, Tatyana
Flaherty, Keith
Sullivan, Ryan J.
Boland, Genevieve Marie
机构：
[1] MGH, Boston, MA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, Ctr Canc, Surg Oncol, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 08期
关键词：
D O I：
10.1200/JCO.2019.37.8_suppl.133
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
133
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The gene-panel obtained by anti-PD-1 monotherapy for melanoma reveals prognostic markers and therapeutic targets
    Wang, Miaomiao
    Zhou, Zhike
    Wang, Yingying
    Wang, Lixin
    JOURNAL OF CHEMOTHERAPY, 2025,
  • [22] Predominance of hyperprogression in mucosal melanoma during anti-PD-1 monotherapy treatment
    Zhou, Li
    Cao, Min
    Zhu, Haibin
    Chi, Zhihong
    Cui, Chuanliang
    Sheng, Xinan
    Mao, Lili
    Lian, Bin
    Tang, Bixia
    Yan, Xieqiao
    Bai, Xue
    Wang, Xuan
    Li, Siming
    Guo, Jun
    Sun, Ying-shi
    Si, Lu
    ONCOLOGIST, 2024,
  • [23] Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-Ad hoc Analyses of Pooled Data From Two Clinical Trials
    Bai, Xue
    Dai, Jie
    Li, Caili
    Cui, Chuanliang
    Mao, Lili
    Wei, Xiaoting
    Sheng, Xinan
    Chi, Zhihong
    Yan, Xieqiao
    Tang, Bixia
    Lian, Bin
    Wang, Xuan
    Zhou, Li
    Li, Siming
    Kong, Yan
    Qi, Zhonghui
    Xu, Huayan
    Duan, Rong
    Guo, Jun
    Si, Lu
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [24] Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
    Joseph, Richard W.
    Cappel, Mark
    Goedjen, Brent
    Gordon, Matthew
    Kirsch, Brandon
    Gilstrap, Cheryl
    Bagaria, Sanjay
    Jambusaria-Pahlajani, Anokhi
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (01) : 18 - 22
  • [25] Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma
    Zhao, Lingdi
    Yang, Yonghao
    Ma, Baozhen
    Li, Wei
    Li, Tiepeng
    Han, Lu
    Zhang, Yong
    Shang, Yi-Man
    Lin, Hongwei
    Gao, Quanli
    JOURNAL OF ONCOLOGY, 2019, 2019
  • [26] Outcomes of retreatment with anti-PD-1 monotherapy after response to first course in patients with cutaneous melanoma
    Whitman, Eric D.
    Scherrer, Emilie
    Ou, Wanmei
    Krepler, Clemens
    FUTURE ONCOLOGY, 2020, 16 (20) : 1441 - 1454
  • [27] Predictable early onset high-dose-glucocorticoid-associated-irAE and its predictive role in anti-PD-1 monotherapy treated advanced melanoma patients.
    Bai, Xue
    Kim, Michelle S.
    Kasumova, Gyulnara
    Chen, Tianqi
    Cohen, Justine Vanessa
    Lawrence, Donald P.
    Freedman, Christine
    Fadden, Riley
    Rubin, Krista M.
    Sharova, Tatyana
    Frederick, Dennie T.
    Flaherty, Keith
    Sullivan, Ryan J.
    Boland, Genevieve Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Prognostic role of plasma levels of γ-glutamyl transpeptidase in patients with advanced gastric cancer treated with anti-PD-1 immunotherapy
    Shaojie Xu
    Yiming Feng
    Xingyin Li
    Zaozao Huang
    Hewei Li
    Ganxin Wang
    Oncology and Translational Medicine, 2022, 8 (03) : 109 - 114
  • [29] Heterogeneous response and irAE patterns in advanced melanoma patients treated with anti-PD-1 monotherapy from different ethnic groups: Subtype distribution discrepancy and beyond.
    Bai, Xue
    Quach, Henry
    Cann, Christopher G.
    Zhang, Michael
    Kim, Michelle S.
    Kasumova, Gyulnara G.
    Si, Lu
    Tang, Bixia
    Cui, Chuanliang
    Yang, Xiaoling
    Wei, Xiaoting
    Cohen, Justine Vanessa
    Lawrence, Donald P.
    Sharova, Tatyana
    Frederick, Dennie T.
    Flaherty, Keith
    Sullivan, Ryan J.
    Boland, Genevieve Marie
    Johnson, Douglas Buckner
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
    Michael A Postow
    Diana M Cardona
    Janis M Taube
    Robert A Anders
    Clive R Taylor
    Jedd D Wolchok
    Margaret K Callahan
    Michael A Curran
    Alexander M Lesokhin
    Joseph F Grosso
    Christine E Horak
    John Cogswell
    Jason S Simon
    Ashok K Gupta
    Mario Sznol
    Journal of Translational Medicine, 12 (Suppl 1)
12345